trastuzumab deruxtecan
daiichi sankyo,astrazeneca
['mbc']
 presenting updated safety data from db03. more nausea, alopecia and discontinuations with tdxd but no deaths from ild and low rate of grade 3. a revolution in treatment for her2+ mbc. #asco2022 